PD-1 / PD-L1 monoclonal antibody Clinical Trials

4 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Also known as: PD -1/PD-L1antibody, Radiotherapy.

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

Suzhou BlueHorse Therapeutics Co., Ltd.1
Repertoire Immune Medicines1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Beijing Tongren Hospital1

Indications

Cancer4
Primary Central Nervous System Lymphoma (PCNSL)1
Advanced Malignant Solid Tumor1
Diffuse Large B-cell Lymphoma(DLBCL)1
Advanced Breast Cancer1

Other3 trials

A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

Phase 2

A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Phase 2

Grand Rapids, Michigan1 trial

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

START Midwest

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.